Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Research Article

Design Expert-supported Method Development and Validation of Cilostazol in Pharmaceutical Formulation Using High-performance Liquid Chromatography

Author(s): Calamur Nagarajan Nalini, Afnaan Afreen and Bhagyalata Satapathy*

Volume 20, Issue 9, 2024

Published on: 29 November, 2024

Page: [1033 - 1042] Pages: 10

DOI: 10.2174/0115734129346572241125111122

Price: $65

Abstract

Background: Developing a simple HPLC method requires an expansive array of literary evidence and experimental routines to perceive the nature of a drug and eventually determine the specific mobile phase and column to be used for attaining better results.

Objectives: The study aimed to develop and optimize a new, simplified, robust, and sensitive method for the determination of cilostazol in tablets by high-performance liquid chromatography using a Box Behnken design.

Methods: The chromatographic separation was carried out on an ODS C18 (4.6 X 250mm and 5μm) column with acetonitrile and methanol (25:75 % v/v) at an effluent flow rate of 1 mL/min and detected at 257 nm.

Results: The method was found to be linear in the concentration range of 10-50 μg/mL, and the correlation coefficient was found to be 0.988, and the recovery of cilostazol was 98.16%. The optimized method validated as per ICH Q2A guidelines was found to be accurate, precise, robust, and stable.

Conclusion: This research thus throws light on the implementation of statistical multivariate analysis techniques used for drug analysis.

Keywords: Quality by design (QBD), response surface methods (RSM), box behnken design, design expert 11, cilostazol, ICH Q2A guidelines.

Graphical Abstract
[1]
Kuruba, S.; Hanamshetty, P. A simple spectrophotometric quantitative determination of Cilostazol in bulk and pharmaceutical dosage forms using DNPH reagent. J. Appl. Pharm. Sci., 2015, 5(12), 117-121.
[http://dx.doi.org/10.7324/JAPS.2015.501220]
[2]
Alhamidehoballah, S.A. Spectrophotometric methods for determination of cilostazol in pure and dosage forms. Int. J. Res. Pharm. Chem., 2015, 5(1), 17-26.
[3]
Kurien, J. HPTLC determination of cilostazol in pharmaceutical dosage forms. Int. J. Adv. Res. (Indore), 2014, 2(2), 952-957.
[4]
Jadhav, A.S.; Pathare, D.B.; Shingare, M.S. A validated stability indicating high performance reverse phase liquid chromatographic method for the determination of cilostazol in bulk drug substance. Drug Dev. Ind. Pharm., 2007, 33(2), 173-179.
[http://dx.doi.org/10.1080/03639040600920366] [PMID: 17454049]
[5]
Bray, L.; Monzani, L.; Brunoldi, E.; Allegrini, P. A validated HPLC/MS limit test method for a potential genotoxic impurity in cilostazol and its quantification in the API and in the commercially available drug product. Sci. Pharm., 2015, 83(2), 269-278.
[http://dx.doi.org/10.3797/scipharm.1502-05] [PMID: 26839820]
[6]
Chavan, A.V.; Gandhimathi, R. Quality by design approach: Progress in pharmaceutical method development and validation. Biomed. Pharmacol. J., 2023, 16(3)
[http://dx.doi.org/10.13005/bpj/2745]
[7]
Babar, S.A.; Padwal, S.L.; Bachute, M.T. Qbd based RP-HPLC method development and validation for simultaneous estimation of amlodipine besylate and lisinopril dihydrate in bulk and pharmaceutical dosage form. J. Pharm. Res. Int., 2021, 33(43A), 143-164.
[http://dx.doi.org/10.9734/jpri/2021/v33i43A32474]
[8]
Raman, N. V. V. S. S. Analytical quality by design approach to test method development and validation in drug substance manufacturing. J. Chem, 2015, 435129.
[9]
Ganorkar, S.B.; Shirkhedkar, A.A. Design of experiments in liquid chromatography (HPLC) analysis of pharmaceuticals: Analytics, applications, implications and future prospects. Rev. Anal. Chem., 2017, 36(3), 20160025.
[http://dx.doi.org/10.1515/revac-2016-0025]
[10]
V, JAYESH. Simultaneous estimation of cilostazol and aspirin in synthetic mixture using hptlc method. Int. J. Chem. Sci., 2008, 6(3), 1377-1384.
[11]
Santhanam, M.K.; Nagarajan, N.C.; Ponraj, P.B.; Mohamed Hilurudeen, M.S. A complete roadmap of analytical quality by design in various analytical techniques. Curr. Pharm. Anal., 2023, 19(3), 184-215.
[http://dx.doi.org/10.2174/1573412919666230118105908]
[12]
Suryawanshi, D.; Jha, D.K.; Shinde, U.; Amin, P.D. Development and validation of a stability-indicating RP-HPLC method of cholecalciferol in bulk and pharmaceutical formulations: Analytical quality by design approach. J. Appl. Pharm. Sci., 2019, 9(6), 21-32.
[http://dx.doi.org/10.7324/JAPS.2019.90604]
[13]
David, K. Application of quality by design (QbD) to the development and validation of analytical methods; Elsevier, 2014.
[http://dx.doi.org/10.1016/B978-0-08-098350-9.00003-5]
[14]
Saha, C.; Gupta, N.V.; Chandan, R.S. Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality by design” approach. Acta Pharm., 2020, 70(1), 17-33.
[http://dx.doi.org/10.2478/acph-2020-0008] [PMID: 31677371]
[15]
Sorkin, E.M.; Markham, A. Cilostazol. Drugs Aging, 1999, 14(1), 63-71.
[http://dx.doi.org/10.2165/00002512-199914010-00005]
[16]
Choi, J.S. Design of cilostazol nanocrystals for improved solubility. J. Pharm. Innov., 2020, 15(3), 416-423.
[http://dx.doi.org/10.1007/s12247-019-09391-7]
[17]
Gresele, P.; Momi, S.; Falcinelli, E. Anti‐platelet therapy: Phosphodiesterase inhibitors. Br. J. Clin. Pharmacol., 2011, 72(4), 634-646.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04034.x] [PMID: 21649691]
[18]
Schrör, K. The pharmacology of cilostazol. Diabetes Obes. Metab., 2002, 4(Suppl. 2), S14-S19.
[http://dx.doi.org/10.1046/j.1463-1326.2002.0040s2s14.x] [PMID: 12180353]
[19]
Sun, B.; Le, S.N.; Lin, S.; Fong, M.; Guertin, M.; Liu, Y.; Tandon, N.N.; Yoshitake, M.; Kambayashi, J. New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation. J. Cardiovasc. Pharmacol., 2002, 40(4), 577-585.
[http://dx.doi.org/10.1097/00005344-200210000-00011] [PMID: 12352320]
[20]
William, R. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects) J. Vasc. Surg., 2008, 47(2), 330-336.
[21]
Al-Rabia, M.W.; Asfour, H.Z.; Alhakamy, N.A.; Bazuhair, M.A.; Ibrahim, T.S.; Abbas, H.A.; Mansour, B.; Hegazy, W.A.H.; Seleem, N.M. Cilostazol is a promising anti-pseudomonal virulence drug by disruption of quorum sensing. AMB Express, 2024, 14(1), 87.
[http://dx.doi.org/10.1186/s13568-024-01740-1] [PMID: 39090255]
[22]
Chang, L.L.; Wu, Y.M.; Wang, H.C.; Tseng, K.Y.; Wang, Y.H.; Lu, Y.M.; Cheng, K.I. Cilostazol ameliorates motor dysfunction and schwann cell impairment in streptozotocin-induced diabetic rats. Int. J. Mol. Sci., 2024, 25(14), 7847.
[http://dx.doi.org/10.3390/ijms25147847] [PMID: 39063088]
[23]
Prickaerts, J.; Heckman, P.R.A.; Blokland, A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for alzheimer’s disease. Expert Opin. Investig. Drugs, 2017, 26(9), 1033-1048.
[http://dx.doi.org/10.1080/13543784.2017.1364360] [PMID: 28772081]
[24]
Rambabu, K.; Suresh, T. Isocratic reversed phase liquid chromatographic method validation for the determination of cilostazol in pure and formulations. Int. J. Pharm. Pharm. Res., 2015, 4(3), 180-192.
[25]
Dharmendra, D.; Karan, M.; Bhoomi, P.; Rajshree, C.M. Quantification of cilostazol and telmisartan in combination using risk profile and uncertainty contour: a contemporary validation approach. J. Chromatogr. Sep. Tech., 2015, 6, 1-8.
[26]
Lestari, A.D.; Palupi, T.; Oktarina, B.; Yuwono, M.; Indrayanto, G. HPLC determination of cilostazol in tablets, and its validation. J. Liq. Chromatogr. Relat. Technol., 2004, 27(16), 2603-2612.
[http://dx.doi.org/10.1081/JLC-200028425]
[27]
Gomes, M.; Traudi, K.; Simionatto, M.; Nadal, J.; Zanin, S.; Borsato, D.; Farago, P. A simple RP-HPLC/UV method for determination of cilostazol in polymeric nanoparticles suspensions: Development and validation. Lat. Am. J. Pharm., 2015, 34, 803-809.
[28]
Damor, D.; Patel, B.P.; Mittal, K.; Mashru, R.C. Simultaneous estimation of cilostazol and telmisartan using PCR, PLS, CLS and ILS. World J. Pharm. Res., 2015, 4(7), 693-709.
[29]
Elkady, E.F.; Tammam, M.H.; El Maaty, A.A. A comparative study of HPLC-UV and UPLC-DAD methods for simultaneous estimation of aspirin and cilostazol in the presence of their related impurities in bulk and capsules. J. Liq. Chromatogr. Relat. Technol., 2017, 40(4), 190-198.
[http://dx.doi.org/10.1080/10826076.2017.1296461]
[30]
R. Pateland, Riddhi. A new RP-HPLC method for simultaneous estimation of telmisartanand cilostazol in synthetic mixture. Int. J. Recent Sci. Res., 2015, 6(4), 3306-3310.
[31]
El-Bagary, R.I.; Elkady, E.F.; Farid, N.A.; Youssef, N.F. A validated spectrophotometric method and thermodynamic studies for the determination of cilostazol and rivaroxaban in pharmaceutical preparations using Fe-phenanthroline system. Anal. Chem. Lett., 2017, 7(5), 676-688.
[http://dx.doi.org/10.1080/22297928.2017.1385420]
[32]
Kalal, D.J.; Redasani, V.K. Stability-indicating RP-HPLC method development and validation for estimation of Mupirocin calcium in bulk and in pharmaceutical formulation. Fut. J. Pharm. Sci., 2022, 8(1), 21.
[http://dx.doi.org/10.1186/s43094-022-00412-w]
[33]
Fayed, A.S.; Shehata, M.A.; Ashour, A.; Hassan, N.Y.; Weshahy, S.A. Validated stability-indicating methods for determination of cilostazol in the presence of its degradation products according to the ICH guidelines. J. Pharm. Biomed. Anal., 2007, 45(3), 407-416.
[http://dx.doi.org/10.1016/j.jpba.2007.06.028] [PMID: 17719736]
[34]
Thomas, A.; Bhosale, S.; Nanda, R. Formulation of solid dosage form containing clopidogrel and cilostazol and its HPLC analysis. Int. J. Pharm. Pharm. Sci., 2017, 9(6), 12-18.
[http://dx.doi.org/10.22159/ijpps.2017v9i6.13987]
[35]
Deokar, Gitanjali Development and validation of UV-spectrophotometric method for estimation of cilostazol in bulk and pharmaceutical dosage form. Int. J. Pharm. Qual. Assur., 2016, 7, 90-97.
[36]
Afreen, A.; Nalini, C.N. An analytical review on the quantitative techniques for estimation of cilostazol in pharmaceutical preparations and biological samples. Rev. Anal. Chem., 2021, 40(1), 58-74.
[http://dx.doi.org/10.1515/revac-2021-0128]
[37]
Basniwal, P.; Kumar, V.; Shrivastav, P.; Jain, D. Spectrophotometric determination of cilostazol in tablet dosage form. Trop. J. Pharm. Res., 2010, 9(5)
[http://dx.doi.org/10.4314/tjpr.v9i5.61066]
[38]
Wassel, A.A. Electrochemical behavior and determination of Cilostazol in pure, urine and in pharmaceutical formulations. Anal. Bioanal. Electrochem., 2012, 4(2), 197-211.
[39]
Patel, J.V. Simultaneous spectrophotometric estimation of cilostazol and aspirin in synthetic mixture. Int. J. Chem. Sci., 2008, 6(1), 73-79.
[40]
Sapna, N.R.; Dedania, Z. R. Simultaneous development and validation of HPTLC method for determination of zonisamide and cilostazol in synthetic mixture. World J. Pharm. Res., 2021, 10(2), 762-771.
[41]
Kurien, J.; Jayasekhar, P. Stability indicating HPLC determination of cilostazol in pharmaceutical dosage forms. Int J Pharm Bio Sci, 2014, 5(1), 176-186.
[42]
Shah, A.B.; Zarna, D.; Jain, V.C. Development and validation of UV spectroscopic simultaneous method for zonisamide and cilostazol in synthetic mixture. Pharma Sci. Monitor, 2019, 10(3), 53-65.
[43]
Joti, J.J. Validation and optimization of a simple RP-HPLC method for determination of cilostazol in human serum. Indian J. Nov. Drug Deliv., 2011, 3(2), 143-148.
[44]
Yeon, K.J.; Park, Y-J.; Park, K-M.; Park, J-S.; Ban, E.; Kim, M-K.; Kim, Y-B.; Kim, C-K. High performance liquid chromatographic analysis of cilostazol in human plasma with on‐line column switching. J. Liq. Chromatogr. Relat. Technol., 2005, 28(1), 109-120.
[http://dx.doi.org/10.1081/JLC-200038606]
[45]
Pareek, D.; Jain, S.; Basniwal, P.K.; Jain, D. RP-HPLC determination of cilostazol in human plasma: Application to pharmacokinetic study in male albino rabbit. Acta Chromatogr., 2014, 26(2), 283-296.
[http://dx.doi.org/10.1556/AChrom.26.2014.2.7]
[46]
Ambekar, A.M.; Kuchekar, B.S. A validated new gradient stability-indicating lc method for the simultaneous estimation of cilostazol and aspirin in bulk and tablet formulation. Eur J Biomed Pharm Sci, 2014, 1(2), 149-164.
[47]
Nirogi, S.; Ramakrishna, V. Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry. Anal. Bioanal. Chem., 2006, 384(3), 780-790.
[48]
Tata, P.N. The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography. J. Pharm. Biomed. Anal., 1998, 18(3), 441-451.
[49]
Fu, C.J. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 1999, 728(2), 251-262.
[50]
Varanasi, V.S. Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. Arzneimittelforschung, 2008, 58(6), 288-296.
[51]
Bramer, S.L.; Tata, P.N.V.; Vengurlekar, S.S.; Brisson, J.H. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J. Pharm. Biomed. Anal., 2001, 26(4), 637-650.
[http://dx.doi.org/10.1016/S0731-7085(01)00436-8] [PMID: 11516916]
[52]
Wang, J. Gradient elution LC-ESI-MS determination of cilostazol in rat plasma and its application. Lat. Am. J. Pharm., 2012, 31(2), 240-244.
[53]
Varanasi, K.K.V.S.; Sridhar, V.; Potharaju, S.; Shraddha, R.; Sivakumar, S.P.N.; Kanaga Sabapathi, S.; Satheeshmanikandan, T.R.S.; Swaroop Kumar, V.V.S. Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 865(1-2), 91-98.
[http://dx.doi.org/10.1016/j.jchromb.2008.02.013] [PMID: 18342586]
[54]
Ibrahim, F.; Sharaf El-Din, M.; El-Aziz, H.A. Selective methods for cilostazol assay in presence of its oxidative degradation product and Co formulated telmisartan application to tablet formulation. J. Chromatogr. Sep. Tech., 2016, 7(335), 2.
[55]
Satheeshmanikandan, T.R.; Sridhar, V.; Kanthikiran, V.V.; Swaroopkumar, V.V.; Mukkanti, K. Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. Arzneimittelforschung, 2012, 62(9), 425-432.
[http://dx.doi.org/10.1055/s-0032-1316374] [PMID: 22821721]
[56]
Maheswari, G. A review on LC-MS/MS in bioanalytical studies. World J. Pharm. Res., 2013, 2(6), 274-278.
[57]
Bhatt, N.M.; Chavada, V.D.; Patel, D.P.; Sharma, P.; Sanyal, M.; Shrivastav, P.S. Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC−MS/MS. J. Pharm. Anal., 2015, 5(1), 1-11.
[http://dx.doi.org/10.1016/j.jpha.2014.08.001] [PMID: 29403909]
[58]
Taleuzzaman, M. Ultra performance liquid chromatography (UPLC)-A review. Austin J. Anal. Pharm. Chem., 2015, 2, 1056.
[59]
Basniwal, P.K.; Shrivastava, P.K.; Jain, D. Hydrolytic degradation profile and RP-HPLC estimation of cilostazol in tablet dosage form. Indian J. Pharm. Sci., 2008, 70(2), 222-224.
[http://dx.doi.org/10.4103/0250-474X.41459] [PMID: 20046716]
[60]
Ch, S.; Amgoth, K.P.; Ks, N.; K, R. Implementing quality by design approach in analytical RP-HPLC method development and validation for the determination of fedratinib. Int. J. Pharm. Sci. Drug Res., 2021, 13(3), 253-262.
[http://dx.doi.org/10.25004/IJPSDR.2021.130303]
[61]
Kepert, J.F.; Cromwell, M.; Engler, N.; Finkler, C.; Gellermann, G.; Gennaro, L.; Harris, R.; Iverson, R.; Kelley, B.; Krummen, L.; McKnight, N.; Motchnik, P.; Schnaible, V.; Taticek, R. Establishing a control system using QbD principles. Biologicals, 2016, 44(5), 319-331.
[http://dx.doi.org/10.1016/j.biologicals.2016.06.003] [PMID: 27430904]
[62]
Pund, S.; Shete, Y.; Jagadale, S. Multivariate analysis of physicochemical characteristics of lipid based nanoemulsifying cilostazol—quality by design Colloids Surf. B Biointerfaces, 2014, 115, 29-36.2014,
[http://dx.doi.org/10.1016/j.colsurfb.2013.11.019]
[63]
Arora, U.; Thakkar, V.; Baldaniya, L.; Gohel, M.C. Fabrication and evaluation of fast disintegrating pellets of cilostazol. Drug Dev. Ind. Pharm., 2020, 46(12), 1927-1946.
[http://dx.doi.org/10.1080/03639045.2020.1826509] [PMID: 33026265]
[64]
Pehlivanoglu, H.; Ocak, M.; Caglar-Andac, S. Application of response surface methodology and quality by design to [68Ga]Ga-PSMA-11 preparation. J. Radioanal. Nucl. Chem., 2024, 333(1), 43-51.
[http://dx.doi.org/10.1007/s10967-023-09246-z]
[65]
Bhattacharya, S. Central composite design for response surface methodology and its application in pharmacy. Response surface methodology in engineering science; Intech Open, 2021.
[66]
Pandey, A.K.; Sara, U.S. Quality by design approach for optimization of 5-fluorouracil microbeads using box–Behnken design and desirability function for colon targeting. J. Pharm. Innov., 2023, 18(4), 2054-2065.
[http://dx.doi.org/10.1007/s12247-023-09772-z]
[67]
Navamanisubramanian, R.; Nerella, R.; Duraipandian, C.; Seetharaman, S. Quality by design approach for optimization of repaglinide buccal tablets using box-Behnken design. Fut. J. Pharm. Sci., 2018, 4(2), 265-272.
[http://dx.doi.org/10.1016/j.fjps.2018.10.002]
[68]
Mutalik, S.P.; Mullick, P.; Pandey, A.; Kulkarni, S.S.; Mutalik, S. Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes. J. Sep. Sci., 2021, 44(15), 2917-2931.
[http://dx.doi.org/10.1002/jssc.202100152] [PMID: 34076952]
[69]
Patel, K.Y.; Dedania, Z.R.; Dedania, R.R.; Patel, U. QbD approach to HPLC method development and validation of ceftriaxone sodium. Fut. J. Pharm. Sci., 2021, 7(1), 141.
[http://dx.doi.org/10.1186/s43094-021-00286-4]
[70]
Kumar, N.; Sangeetha, D. Analytical method development by using QbD-An emerging approach for robust analytical method development. J. Pharm. Sci. Res., 2020, 12(10), 1298-1305.
[71]
Bangham, A.D. Membrane models with phospholipids. Prog. Biophys. Mol. Biol., 1968, 18, 29-95.
[http://dx.doi.org/10.1016/0079-6107(68)90019-9] [PMID: 4894874]
[72]
Hu, Z.; Gao, S.; Gao, J. Investigation and structural elucidation of a new impurity in bulk drug of cilostazol by LC/MS/MS, FT-IR and NMR. J. Pharm. Biomed. Anal., 2017, 145, 16-23.
[http://dx.doi.org/10.1016/j.jpba.2017.06.019] [PMID: 28646658]
[73]
Choi, D.H.; Choi, J.S. Cilostazol solubilization and stabilization using a polymer-free solid dispersion system. J. Pharm. Innov., 2022, 17(2), 521-533.
[http://dx.doi.org/10.1007/s12247-021-09533-w]

© 2025 Bentham Science Publishers | Privacy Policy